title: Longitudinal changes in photopic OPs occurring with vigabatrin treatment.
abstract: OBJECTIVE
  Vigabatrin (gamma-vinyl-GABA) is an antiepileptic drug successful in the management of infantile spasms. Photopic ERGs were tested in children followed longitudinally before and during vigabatrin treatment.
  
  
  METHODS
  Subjects were 26 infants (age range 1.5-24 months, median 7.6 months) on vigabatrin treatment who had been tested on multiple visits (two to four visits; mean, three visits). Eighteen of these were assessed initially before starting vigabatrin therapy and eight were assessed within 1 week of initiation of the drug. ERGs were recorded at 6-month intervals. Standard ISCEV protocol with Burian-Allen bipolar contact-lens electrodes (standard flash 2.0 cd.s/m2) was used. Although ISCEV standards were followed, a higher flash intensity (set at 3.6 cd.s/m2) was chosen for single-flash cone assessment to provide a better definition of OPs. Photopic OPs were divided into categories of early OPs and late OP (OP4). Responses were compared with age corrected limits extrapolated from our lab control database.
  
  
  RESULTS
  Results showed differential effects of vigabatrin on the summed early OP amplitudes versus the late OP (OP4) and cone b-wave amplitude. The early OPs showed significant decrease (p = 0.0005, repeated measures analysis of variance) after 6 months and remained decreased for the duration of treatment. There was no significant change seen in the late OP. The cone b-wave amplitude showed initial increase (p = 0.04) after 6 months, followed by a decrease after 18 months; a trend similar to that of the late OP.
  
  
  CONCLUSIONS
  Early photopic OPs were disrupted more than the late OP, suggesting relative deficit in the ON (depolarizing) retinal pathways.
authors.affiliation: Department of Ophthalmology, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
authors.forename: Sharon
authors.initials: S
authors.lastname: Morong
authors.forename: Carol A
authors.initials: CA
authors.lastname: Westall
authors.forename: Rita
authors.initials: R
authors.lastname: Nobile
authors.forename: J Raymond
authors.initials: JR
authors.lastname: Buncic
authors.forename: William J
authors.initials: WJ
authors.lastname: Logan
authors.forename: Carole M
authors.initials: CM
authors.lastname: Panton
authors.forename: Mohamed
authors.initials: M
authors.lastname: Abdolell
mesh_terms: D000927:Anticonvulsants / Q000009:adverse effects* / Q000627:therapeutic use; D002675:Child, Preschool; D004596:Electroretinography / Q000187:drug effects*; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D010775:Photic Stimulation; D020419:Photoreceptor Cells, Vertebrate / Q000187:drug effects* / Q000502:physiology; D013036:Spasms, Infantile / Q000188:drug therapy; D020888:Vigabatrin / Q000009:adverse effects* / Q000627:therapeutic use; D014786:Vision Disorders / Q000139:chemically induced* / Q000503:physiopathology; D014795:Visual Pathways / Q000187:drug effects* / Q000503:physiopathology
chemical_list: D000927:Anticonvulsants; D020888:Vigabatrin